|
WO2015123598A1
|
|
Biomarkers for cardiovascular disease
|
|
US2017138960A1
|
|
Detection, monitoring and treatment of acute myocardial infarction
|
|
WO2015085314A2
|
|
Methods for detection of heart failure
|
|
WO2015058158A1
|
|
METHOD FOR DETECTION OF LIPOPROTEIN-SPECIFIC Lp-PLA2 ASSOCIATION
|
|
EP3049813A2
|
|
Long shelf-life kits and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase a2
|
|
US2014283157A1
|
|
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
|
CA2798122A1
|
|
Methods using lipoprotein-associated phospholipase a2 in an acute care setting
|
|
WO2008103701A2
|
|
Ovr115 antibody compositions and methods of use
|
|
EP2104513A2
|
|
Ovr110 antibody compositions and methods of use
|
|
US2010150907A1
|
|
PRO115 antibody compositions and methods of use
|
|
WO2007112330A2
|
|
Compositions and methods for detection, prognosis and treatment of colon cancer
|
|
WO2007076465A2
|
|
Cln248 antibody compositions and methods of use
|
|
WO2007016590A2
|
|
Ovr232v3 antibody compositions and methods of use
|
|
WO2006121991A2
|
|
Compositions and methods for detection, prognosis and treatment of breast cancer
|
|
US2008199461A1
|
|
Ovr110 antibody compositions and methods of use
|
|
AU2005304462A1
|
|
Ovr110 antibody compositions and methods of use
|
|
WO2007001399A2
|
|
Compositions, splice variants and methods relating to cancer specific genes and proteins
|
|
WO2005095454A1
|
|
Lng105 antibody composition and methods of use, and use of lng105 to assess lung cancer risk
|
|
EP1718967A2
|
|
METHODS OF DETECTING Lp-PLA2 ACTIVITY
|
|
WO2005044075A2
|
|
Compositions, splice variants and methods relating to breast specific genes and proteins
|
